Efficacy and safety of dupilumab with concomitant topical corticosteroids in Japanese pediatric patients with moderate-to-severe atopic dermatitis: A randomized, double-blind, placebo-controlled phase 3 study Article Swipe
Motohiro Ebisawa
,
Yoko Kataoka
,
Akio Tanaka
,
Mizuho Nagao
,
Elizabeth Laws
,
Eric Mortensen
,
Hisakatsu Nawata
,
Kazuhiko Arima
,
Daisuke Watanabe
,
Xin Lu
,
Jennifer Maloney
,
Ariane Dubost-Brama
,
Ashish Bansal
,
Kenji Yahata
·
YOU?
·
· 2024
· Open Access
·
· DOI: https://doi.org/10.1016/j.alit.2024.04.006
YOU?
·
· 2024
· Open Access
·
· DOI: https://doi.org/10.1016/j.alit.2024.04.006
Dupilumab showed consistent efficacy and was well tolerated in Japanese patients aged ≥6 months to <18 years with moderate-to-severe atopic dermatitis previously insufficiently controlled with existing therapies.
Related Topics
Concepts
Metadata
- Type
- article
- Language
- en
- Landing Page
- https://doi.org/10.1016/j.alit.2024.04.006
- OA Status
- gold
- Cited By
- 7
- References
- 34
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W4396836103
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W4396836103Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.1016/j.alit.2024.04.006Digital Object Identifier
- Title
-
Efficacy and safety of dupilumab with concomitant topical corticosteroids in Japanese pediatric patients with moderate-to-severe atopic dermatitis: A randomized, double-blind, placebo-controlled phase 3 studyWork title
- Type
-
articleOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2024Year of publication
- Publication date
-
2024-05-11Full publication date if available
- Authors
-
Motohiro Ebisawa, Yoko Kataoka, Akio Tanaka, Mizuho Nagao, Elizabeth Laws, Eric Mortensen, Hisakatsu Nawata, Kazuhiko Arima, Daisuke Watanabe, Xin Lu, Jennifer Maloney, Ariane Dubost-Brama, Ashish Bansal, Kenji YahataList of authors in order
- Landing page
-
https://doi.org/10.1016/j.alit.2024.04.006Publisher landing page
- Open access
-
YesWhether a free full text is available
- OA status
-
goldOpen access status per OpenAlex
- OA URL
-
https://doi.org/10.1016/j.alit.2024.04.006Direct OA link when available
- Concepts
-
Atopic dermatitis, Medicine, Dupilumab, Concomitant, Dermatology, Placebo, Randomized controlled trial, Double blind, Internal medicine, Alternative medicine, PathologyTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
7Total citation count in OpenAlex
- Citations by year (recent)
-
2025: 6, 2024: 1Per-year citation counts (last 5 years)
- References (count)
-
34Number of works referenced by this work
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W4396836103 |
|---|---|
| doi | https://doi.org/10.1016/j.alit.2024.04.006 |
| ids.doi | https://doi.org/10.1016/j.alit.2024.04.006 |
| ids.pmid | https://pubmed.ncbi.nlm.nih.gov/38735810 |
| ids.openalex | https://openalex.org/W4396836103 |
| fwci | 8.30754582 |
| mesh[0].qualifier_ui | |
| mesh[0].descriptor_ui | D006801 |
| mesh[0].is_major_topic | False |
| mesh[0].qualifier_name | |
| mesh[0].descriptor_name | Humans |
| mesh[1].qualifier_ui | Q000188 |
| mesh[1].descriptor_ui | D003876 |
| mesh[1].is_major_topic | True |
| mesh[1].qualifier_name | drug therapy |
| mesh[1].descriptor_name | Dermatitis, Atopic |
| mesh[2].qualifier_ui | |
| mesh[2].descriptor_ui | D002648 |
| mesh[2].is_major_topic | False |
| mesh[2].qualifier_name | |
| mesh[2].descriptor_name | Child |
| mesh[3].qualifier_ui | Q000008 |
| mesh[3].descriptor_ui | D061067 |
| mesh[3].is_major_topic | True |
| mesh[3].qualifier_name | administration & dosage |
| mesh[3].descriptor_name | Antibodies, Monoclonal, Humanized |
| mesh[4].qualifier_ui | Q000627 |
| mesh[4].descriptor_ui | D061067 |
| mesh[4].is_major_topic | True |
| mesh[4].qualifier_name | therapeutic use |
| mesh[4].descriptor_name | Antibodies, Monoclonal, Humanized |
| mesh[5].qualifier_ui | Q000009 |
| mesh[5].descriptor_ui | D061067 |
| mesh[5].is_major_topic | True |
| mesh[5].qualifier_name | adverse effects |
| mesh[5].descriptor_name | Antibodies, Monoclonal, Humanized |
| mesh[6].qualifier_ui | |
| mesh[6].descriptor_ui | D008297 |
| mesh[6].is_major_topic | False |
| mesh[6].qualifier_name | |
| mesh[6].descriptor_name | Male |
| mesh[7].qualifier_ui | |
| mesh[7].descriptor_ui | D005260 |
| mesh[7].is_major_topic | False |
| mesh[7].qualifier_name | |
| mesh[7].descriptor_name | Female |
| mesh[8].qualifier_ui | |
| mesh[8].descriptor_ui | D002675 |
| mesh[8].is_major_topic | False |
| mesh[8].qualifier_name | |
| mesh[8].descriptor_name | Child, Preschool |
| mesh[9].qualifier_ui | |
| mesh[9].descriptor_ui | D016896 |
| mesh[9].is_major_topic | False |
| mesh[9].qualifier_name | |
| mesh[9].descriptor_name | Treatment Outcome |
| mesh[10].qualifier_ui | Q000627 |
| mesh[10].descriptor_ui | D000305 |
| mesh[10].is_major_topic | True |
| mesh[10].qualifier_name | therapeutic use |
| mesh[10].descriptor_name | Adrenal Cortex Hormones |
| mesh[11].qualifier_ui | Q000008 |
| mesh[11].descriptor_ui | D000305 |
| mesh[11].is_major_topic | True |
| mesh[11].qualifier_name | administration & dosage |
| mesh[11].descriptor_name | Adrenal Cortex Hormones |
| mesh[12].qualifier_ui | |
| mesh[12].descriptor_ui | D000293 |
| mesh[12].is_major_topic | False |
| mesh[12].qualifier_name | |
| mesh[12].descriptor_name | Adolescent |
| mesh[13].qualifier_ui | |
| mesh[13].descriptor_ui | D012720 |
| mesh[13].is_major_topic | True |
| mesh[13].qualifier_name | |
| mesh[13].descriptor_name | Severity of Illness Index |
| mesh[14].qualifier_ui | |
| mesh[14].descriptor_ui | D004311 |
| mesh[14].is_major_topic | False |
| mesh[14].qualifier_name | |
| mesh[14].descriptor_name | Double-Blind Method |
| mesh[15].qualifier_ui | |
| mesh[15].descriptor_ui | D007223 |
| mesh[15].is_major_topic | False |
| mesh[15].qualifier_name | |
| mesh[15].descriptor_name | Infant |
| mesh[16].qualifier_ui | |
| mesh[16].descriptor_ui | D007564 |
| mesh[16].is_major_topic | False |
| mesh[16].qualifier_name | |
| mesh[16].descriptor_name | Japan |
| mesh[17].qualifier_ui | |
| mesh[17].descriptor_ui | D004359 |
| mesh[17].is_major_topic | False |
| mesh[17].qualifier_name | |
| mesh[17].descriptor_name | Drug Therapy, Combination |
| mesh[18].qualifier_ui | |
| mesh[18].descriptor_ui | D000287 |
| mesh[18].is_major_topic | False |
| mesh[18].qualifier_name | |
| mesh[18].descriptor_name | Administration, Topical |
| mesh[19].qualifier_ui | |
| mesh[19].descriptor_ui | D000095225 |
| mesh[19].is_major_topic | False |
| mesh[19].qualifier_name | |
| mesh[19].descriptor_name | East Asian People |
| mesh[20].qualifier_ui | |
| mesh[20].descriptor_ui | D006801 |
| mesh[20].is_major_topic | False |
| mesh[20].qualifier_name | |
| mesh[20].descriptor_name | Humans |
| mesh[21].qualifier_ui | Q000188 |
| mesh[21].descriptor_ui | D003876 |
| mesh[21].is_major_topic | True |
| mesh[21].qualifier_name | drug therapy |
| mesh[21].descriptor_name | Dermatitis, Atopic |
| mesh[22].qualifier_ui | |
| mesh[22].descriptor_ui | D002648 |
| mesh[22].is_major_topic | False |
| mesh[22].qualifier_name | |
| mesh[22].descriptor_name | Child |
| mesh[23].qualifier_ui | Q000008 |
| mesh[23].descriptor_ui | D061067 |
| mesh[23].is_major_topic | True |
| mesh[23].qualifier_name | administration & dosage |
| mesh[23].descriptor_name | Antibodies, Monoclonal, Humanized |
| mesh[24].qualifier_ui | Q000627 |
| mesh[24].descriptor_ui | D061067 |
| mesh[24].is_major_topic | True |
| mesh[24].qualifier_name | therapeutic use |
| mesh[24].descriptor_name | Antibodies, Monoclonal, Humanized |
| mesh[25].qualifier_ui | Q000009 |
| mesh[25].descriptor_ui | D061067 |
| mesh[25].is_major_topic | True |
| mesh[25].qualifier_name | adverse effects |
| mesh[25].descriptor_name | Antibodies, Monoclonal, Humanized |
| mesh[26].qualifier_ui | |
| mesh[26].descriptor_ui | D008297 |
| mesh[26].is_major_topic | False |
| mesh[26].qualifier_name | |
| mesh[26].descriptor_name | Male |
| mesh[27].qualifier_ui | |
| mesh[27].descriptor_ui | D005260 |
| mesh[27].is_major_topic | False |
| mesh[27].qualifier_name | |
| mesh[27].descriptor_name | Female |
| mesh[28].qualifier_ui | |
| mesh[28].descriptor_ui | D002675 |
| mesh[28].is_major_topic | False |
| mesh[28].qualifier_name | |
| mesh[28].descriptor_name | Child, Preschool |
| mesh[29].qualifier_ui | |
| mesh[29].descriptor_ui | D016896 |
| mesh[29].is_major_topic | False |
| mesh[29].qualifier_name | |
| mesh[29].descriptor_name | Treatment Outcome |
| mesh[30].qualifier_ui | Q000627 |
| mesh[30].descriptor_ui | D000305 |
| mesh[30].is_major_topic | True |
| mesh[30].qualifier_name | therapeutic use |
| mesh[30].descriptor_name | Adrenal Cortex Hormones |
| mesh[31].qualifier_ui | Q000008 |
| mesh[31].descriptor_ui | D000305 |
| mesh[31].is_major_topic | True |
| mesh[31].qualifier_name | administration & dosage |
| mesh[31].descriptor_name | Adrenal Cortex Hormones |
| mesh[32].qualifier_ui | |
| mesh[32].descriptor_ui | D000293 |
| mesh[32].is_major_topic | False |
| mesh[32].qualifier_name | |
| mesh[32].descriptor_name | Adolescent |
| mesh[33].qualifier_ui | |
| mesh[33].descriptor_ui | D012720 |
| mesh[33].is_major_topic | True |
| mesh[33].qualifier_name | |
| mesh[33].descriptor_name | Severity of Illness Index |
| mesh[34].qualifier_ui | |
| mesh[34].descriptor_ui | D004311 |
| mesh[34].is_major_topic | False |
| mesh[34].qualifier_name | |
| mesh[34].descriptor_name | Double-Blind Method |
| mesh[35].qualifier_ui | |
| mesh[35].descriptor_ui | D007223 |
| mesh[35].is_major_topic | False |
| mesh[35].qualifier_name | |
| mesh[35].descriptor_name | Infant |
| mesh[36].qualifier_ui | |
| mesh[36].descriptor_ui | D007564 |
| mesh[36].is_major_topic | False |
| mesh[36].qualifier_name | |
| mesh[36].descriptor_name | Japan |
| mesh[37].qualifier_ui | |
| mesh[37].descriptor_ui | D004359 |
| mesh[37].is_major_topic | False |
| mesh[37].qualifier_name | |
| mesh[37].descriptor_name | Drug Therapy, Combination |
| mesh[38].qualifier_ui | |
| mesh[38].descriptor_ui | D000287 |
| mesh[38].is_major_topic | False |
| mesh[38].qualifier_name | |
| mesh[38].descriptor_name | Administration, Topical |
| mesh[39].qualifier_ui | |
| mesh[39].descriptor_ui | D000095225 |
| mesh[39].is_major_topic | False |
| mesh[39].qualifier_name | |
| mesh[39].descriptor_name | East Asian People |
| mesh[40].qualifier_ui | |
| mesh[40].descriptor_ui | D006801 |
| mesh[40].is_major_topic | False |
| mesh[40].qualifier_name | |
| mesh[40].descriptor_name | Humans |
| mesh[41].qualifier_ui | Q000188 |
| mesh[41].descriptor_ui | D003876 |
| mesh[41].is_major_topic | True |
| mesh[41].qualifier_name | drug therapy |
| mesh[41].descriptor_name | Dermatitis, Atopic |
| mesh[42].qualifier_ui | |
| mesh[42].descriptor_ui | D002648 |
| mesh[42].is_major_topic | False |
| mesh[42].qualifier_name | |
| mesh[42].descriptor_name | Child |
| mesh[43].qualifier_ui | Q000008 |
| mesh[43].descriptor_ui | D061067 |
| mesh[43].is_major_topic | True |
| mesh[43].qualifier_name | administration & dosage |
| mesh[43].descriptor_name | Antibodies, Monoclonal, Humanized |
| mesh[44].qualifier_ui | Q000627 |
| mesh[44].descriptor_ui | D061067 |
| mesh[44].is_major_topic | True |
| mesh[44].qualifier_name | therapeutic use |
| mesh[44].descriptor_name | Antibodies, Monoclonal, Humanized |
| mesh[45].qualifier_ui | Q000009 |
| mesh[45].descriptor_ui | D061067 |
| mesh[45].is_major_topic | True |
| mesh[45].qualifier_name | adverse effects |
| mesh[45].descriptor_name | Antibodies, Monoclonal, Humanized |
| mesh[46].qualifier_ui | |
| mesh[46].descriptor_ui | D008297 |
| mesh[46].is_major_topic | False |
| mesh[46].qualifier_name | |
| mesh[46].descriptor_name | Male |
| mesh[47].qualifier_ui | |
| mesh[47].descriptor_ui | D005260 |
| mesh[47].is_major_topic | False |
| mesh[47].qualifier_name | |
| mesh[47].descriptor_name | Female |
| mesh[48].qualifier_ui | |
| mesh[48].descriptor_ui | D002675 |
| mesh[48].is_major_topic | False |
| mesh[48].qualifier_name | |
| mesh[48].descriptor_name | Child, Preschool |
| mesh[49].qualifier_ui | |
| mesh[49].descriptor_ui | D016896 |
| mesh[49].is_major_topic | False |
| mesh[49].qualifier_name | |
| mesh[49].descriptor_name | Treatment Outcome |
| type | article |
| title | Efficacy and safety of dupilumab with concomitant topical corticosteroids in Japanese pediatric patients with moderate-to-severe atopic dermatitis: A randomized, double-blind, placebo-controlled phase 3 study |
| biblio.issue | 4 |
| biblio.volume | 73 |
| biblio.last_page | 542 |
| biblio.first_page | 532 |
| grants[0].funder | https://openalex.org/F4320307781 |
| grants[0].award_id | |
| grants[0].funder_display_name | Sanofi |
| grants[1].funder | https://openalex.org/F4320333907 |
| grants[1].award_id | |
| grants[1].funder_display_name | Sanofi K.K. |
| topics[0].id | https://openalex.org/T10837 |
| topics[0].field.id | https://openalex.org/fields/27 |
| topics[0].field.display_name | Medicine |
| topics[0].score | 1.0 |
| topics[0].domain.id | https://openalex.org/domains/4 |
| topics[0].domain.display_name | Health Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/2708 |
| topics[0].subfield.display_name | Dermatology |
| topics[0].display_name | Dermatology and Skin Diseases |
| topics[1].id | https://openalex.org/T10877 |
| topics[1].field.id | https://openalex.org/fields/27 |
| topics[1].field.display_name | Medicine |
| topics[1].score | 0.992900013923645 |
| topics[1].domain.id | https://openalex.org/domains/4 |
| topics[1].domain.display_name | Health Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/2723 |
| topics[1].subfield.display_name | Immunology and Allergy |
| topics[1].display_name | Allergic Rhinitis and Sensitization |
| topics[2].id | https://openalex.org/T10051 |
| topics[2].field.id | https://openalex.org/fields/27 |
| topics[2].field.display_name | Medicine |
| topics[2].score | 0.989300012588501 |
| topics[2].domain.id | https://openalex.org/domains/4 |
| topics[2].domain.display_name | Health Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/2737 |
| topics[2].subfield.display_name | Physiology |
| topics[2].display_name | Asthma and respiratory diseases |
| funders[0].id | https://openalex.org/F4320307781 |
| funders[0].ror | https://ror.org/027vj4x92 |
| funders[0].display_name | Sanofi |
| funders[1].id | https://openalex.org/F4320333907 |
| funders[1].ror | |
| funders[1].display_name | Sanofi K.K. |
| is_xpac | False |
| apc_list.value | 2280 |
| apc_list.currency | USD |
| apc_list.value_usd | 2280 |
| apc_paid.value | 2280 |
| apc_paid.currency | USD |
| apc_paid.value_usd | 2280 |
| concepts[0].id | https://openalex.org/C2778329239 |
| concepts[0].level | 2 |
| concepts[0].score | 0.8570221662521362 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q268667 |
| concepts[0].display_name | Atopic dermatitis |
| concepts[1].id | https://openalex.org/C71924100 |
| concepts[1].level | 0 |
| concepts[1].score | 0.8204898238182068 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[1].display_name | Medicine |
| concepts[2].id | https://openalex.org/C2779824493 |
| concepts[2].level | 3 |
| concepts[2].score | 0.8140181303024292 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q5315925 |
| concepts[2].display_name | Dupilumab |
| concepts[3].id | https://openalex.org/C2779384505 |
| concepts[3].level | 2 |
| concepts[3].score | 0.7567046880722046 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q17007513 |
| concepts[3].display_name | Concomitant |
| concepts[4].id | https://openalex.org/C16005928 |
| concepts[4].level | 1 |
| concepts[4].score | 0.6269767880439758 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q171171 |
| concepts[4].display_name | Dermatology |
| concepts[5].id | https://openalex.org/C27081682 |
| concepts[5].level | 3 |
| concepts[5].score | 0.5826000571250916 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q269829 |
| concepts[5].display_name | Placebo |
| concepts[6].id | https://openalex.org/C168563851 |
| concepts[6].level | 2 |
| concepts[6].score | 0.46610555052757263 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q1436668 |
| concepts[6].display_name | Randomized controlled trial |
| concepts[7].id | https://openalex.org/C2991744798 |
| concepts[7].level | 4 |
| concepts[7].score | 0.45140090584754944 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q608510 |
| concepts[7].display_name | Double blind |
| concepts[8].id | https://openalex.org/C126322002 |
| concepts[8].level | 1 |
| concepts[8].score | 0.23063841462135315 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q11180 |
| concepts[8].display_name | Internal medicine |
| concepts[9].id | https://openalex.org/C204787440 |
| concepts[9].level | 2 |
| concepts[9].score | 0.058317720890045166 |
| concepts[9].wikidata | https://www.wikidata.org/wiki/Q188504 |
| concepts[9].display_name | Alternative medicine |
| concepts[10].id | https://openalex.org/C142724271 |
| concepts[10].level | 1 |
| concepts[10].score | 0.0 |
| concepts[10].wikidata | https://www.wikidata.org/wiki/Q7208 |
| concepts[10].display_name | Pathology |
| keywords[0].id | https://openalex.org/keywords/atopic-dermatitis |
| keywords[0].score | 0.8570221662521362 |
| keywords[0].display_name | Atopic dermatitis |
| keywords[1].id | https://openalex.org/keywords/medicine |
| keywords[1].score | 0.8204898238182068 |
| keywords[1].display_name | Medicine |
| keywords[2].id | https://openalex.org/keywords/dupilumab |
| keywords[2].score | 0.8140181303024292 |
| keywords[2].display_name | Dupilumab |
| keywords[3].id | https://openalex.org/keywords/concomitant |
| keywords[3].score | 0.7567046880722046 |
| keywords[3].display_name | Concomitant |
| keywords[4].id | https://openalex.org/keywords/dermatology |
| keywords[4].score | 0.6269767880439758 |
| keywords[4].display_name | Dermatology |
| keywords[5].id | https://openalex.org/keywords/placebo |
| keywords[5].score | 0.5826000571250916 |
| keywords[5].display_name | Placebo |
| keywords[6].id | https://openalex.org/keywords/randomized-controlled-trial |
| keywords[6].score | 0.46610555052757263 |
| keywords[6].display_name | Randomized controlled trial |
| keywords[7].id | https://openalex.org/keywords/double-blind |
| keywords[7].score | 0.45140090584754944 |
| keywords[7].display_name | Double blind |
| keywords[8].id | https://openalex.org/keywords/internal-medicine |
| keywords[8].score | 0.23063841462135315 |
| keywords[8].display_name | Internal medicine |
| keywords[9].id | https://openalex.org/keywords/alternative-medicine |
| keywords[9].score | 0.058317720890045166 |
| keywords[9].display_name | Alternative medicine |
| language | en |
| locations[0].id | doi:10.1016/j.alit.2024.04.006 |
| locations[0].is_oa | True |
| locations[0].source.id | https://openalex.org/S116585092 |
| locations[0].source.issn | 1323-8930, 1440-1592 |
| locations[0].source.type | journal |
| locations[0].source.is_oa | True |
| locations[0].source.issn_l | 1323-8930 |
| locations[0].source.is_core | True |
| locations[0].source.is_in_doaj | True |
| locations[0].source.display_name | Allergology International |
| locations[0].source.host_organization | https://openalex.org/P4310320990 |
| locations[0].source.host_organization_name | Elsevier BV |
| locations[0].source.host_organization_lineage | https://openalex.org/P4310320990 |
| locations[0].license | cc-by-nc-nd |
| locations[0].pdf_url | |
| locations[0].version | publishedVersion |
| locations[0].raw_type | journal-article |
| locations[0].license_id | https://openalex.org/licenses/cc-by-nc-nd |
| locations[0].is_accepted | True |
| locations[0].is_published | True |
| locations[0].raw_source_name | Allergology International |
| locations[0].landing_page_url | https://doi.org/10.1016/j.alit.2024.04.006 |
| locations[1].id | pmid:38735810 |
| locations[1].is_oa | False |
| locations[1].source.id | https://openalex.org/S4306525036 |
| locations[1].source.issn | |
| locations[1].source.type | repository |
| locations[1].source.is_oa | False |
| locations[1].source.issn_l | |
| locations[1].source.is_core | False |
| locations[1].source.is_in_doaj | False |
| locations[1].source.display_name | PubMed |
| locations[1].source.host_organization | https://openalex.org/I1299303238 |
| locations[1].source.host_organization_name | National Institutes of Health |
| locations[1].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[1].license | |
| locations[1].pdf_url | |
| locations[1].version | publishedVersion |
| locations[1].raw_type | |
| locations[1].license_id | |
| locations[1].is_accepted | True |
| locations[1].is_published | True |
| locations[1].raw_source_name | Allergology international : official journal of the Japanese Society of Allergology |
| locations[1].landing_page_url | https://pubmed.ncbi.nlm.nih.gov/38735810 |
| locations[2].id | pmh:oai:doaj.org/article:54821419f674416dbe93987dd4251fbf |
| locations[2].is_oa | False |
| locations[2].source.id | https://openalex.org/S4306401280 |
| locations[2].source.issn | |
| locations[2].source.type | repository |
| locations[2].source.is_oa | False |
| locations[2].source.issn_l | |
| locations[2].source.is_core | False |
| locations[2].source.is_in_doaj | False |
| locations[2].source.display_name | DOAJ (DOAJ: Directory of Open Access Journals) |
| locations[2].source.host_organization | |
| locations[2].source.host_organization_name | |
| locations[2].source.host_organization_lineage | |
| locations[2].license | |
| locations[2].pdf_url | |
| locations[2].version | submittedVersion |
| locations[2].raw_type | article |
| locations[2].license_id | |
| locations[2].is_accepted | False |
| locations[2].is_published | False |
| locations[2].raw_source_name | Allergology International, Vol 73, Iss 4, Pp 532-542 (2024) |
| locations[2].landing_page_url | https://doaj.org/article/54821419f674416dbe93987dd4251fbf |
| indexed_in | crossref, doaj, pubmed |
| authorships[0].author.id | https://openalex.org/A5057294669 |
| authorships[0].author.orcid | https://orcid.org/0000-0003-4117-558X |
| authorships[0].author.display_name | Motohiro Ebisawa |
| authorships[0].countries | JP |
| authorships[0].affiliations[0].institution_ids | https://openalex.org/I4210115833 |
| authorships[0].affiliations[0].raw_affiliation_string | Clinical Research Center for Allergy and Rheumatology, NHO Sagamihara National Hospital, Sagamihara, Japan |
| authorships[0].institutions[0].id | https://openalex.org/I4210115833 |
| authorships[0].institutions[0].ror | https://ror.org/01gvfxs59 |
| authorships[0].institutions[0].type | healthcare |
| authorships[0].institutions[0].lineage | https://openalex.org/I4210115833, https://openalex.org/I4210137409 |
| authorships[0].institutions[0].country_code | JP |
| authorships[0].institutions[0].display_name | National Sagamihara Hospital |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Motohiro Ebisawa |
| authorships[0].is_corresponding | True |
| authorships[0].raw_affiliation_strings | Clinical Research Center for Allergy and Rheumatology, NHO Sagamihara National Hospital, Sagamihara, Japan |
| authorships[1].author.id | https://openalex.org/A5018906077 |
| authorships[1].author.orcid | https://orcid.org/0000-0001-6268-6587 |
| authorships[1].author.display_name | Yoko Kataoka |
| authorships[1].countries | JP |
| authorships[1].affiliations[0].institution_ids | https://openalex.org/I3019022944 |
| authorships[1].affiliations[0].raw_affiliation_string | Department of Dermatology, Osaka Habikino Medical Center, Osaka, Japan |
| authorships[1].institutions[0].id | https://openalex.org/I3019022944 |
| authorships[1].institutions[0].ror | https://ror.org/00vcb6036 |
| authorships[1].institutions[0].type | healthcare |
| authorships[1].institutions[0].lineage | https://openalex.org/I3019022944 |
| authorships[1].institutions[0].country_code | JP |
| authorships[1].institutions[0].display_name | Osaka Prefectural Medical Center |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Yoko Kataoka |
| authorships[1].is_corresponding | False |
| authorships[1].raw_affiliation_strings | Department of Dermatology, Osaka Habikino Medical Center, Osaka, Japan |
| authorships[2].author.id | https://openalex.org/A5037599908 |
| authorships[2].author.orcid | https://orcid.org/0000-0002-5354-7064 |
| authorships[2].author.display_name | Akio Tanaka |
| authorships[2].countries | JP |
| authorships[2].affiliations[0].institution_ids | https://openalex.org/I113306721 |
| authorships[2].affiliations[0].raw_affiliation_string | Department of Dermatology, Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima, Japan |
| authorships[2].institutions[0].id | https://openalex.org/I113306721 |
| authorships[2].institutions[0].ror | https://ror.org/03t78wx29 |
| authorships[2].institutions[0].type | education |
| authorships[2].institutions[0].lineage | https://openalex.org/I113306721 |
| authorships[2].institutions[0].country_code | JP |
| authorships[2].institutions[0].display_name | Hiroshima University |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | Akio Tanaka |
| authorships[2].is_corresponding | False |
| authorships[2].raw_affiliation_strings | Department of Dermatology, Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima, Japan |
| authorships[3].author.id | https://openalex.org/A5062741202 |
| authorships[3].author.orcid | https://orcid.org/0000-0003-3557-8761 |
| authorships[3].author.display_name | Mizuho Nagao |
| authorships[3].countries | JP |
| authorships[3].affiliations[0].institution_ids | https://openalex.org/I4210148597 |
| authorships[3].affiliations[0].raw_affiliation_string | Allergy Center and Infectious Disease Center, NHO Mie National Hospital, Tsu, Japan |
| authorships[3].institutions[0].id | https://openalex.org/I4210148597 |
| authorships[3].institutions[0].ror | https://ror.org/04q0b3c27 |
| authorships[3].institutions[0].type | healthcare |
| authorships[3].institutions[0].lineage | https://openalex.org/I4210148597 |
| authorships[3].institutions[0].country_code | JP |
| authorships[3].institutions[0].display_name | National Mie Hospital |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | Mizuho Nagao |
| authorships[3].is_corresponding | False |
| authorships[3].raw_affiliation_strings | Allergy Center and Infectious Disease Center, NHO Mie National Hospital, Tsu, Japan |
| authorships[4].author.id | https://openalex.org/A5017155583 |
| authorships[4].author.orcid | |
| authorships[4].author.display_name | Elizabeth Laws |
| authorships[4].countries | US |
| authorships[4].affiliations[0].institution_ids | https://openalex.org/I4210111804 |
| authorships[4].affiliations[0].raw_affiliation_string | Sanofi, Bridgewater, NJ, USA |
| authorships[4].institutions[0].id | https://openalex.org/I4210111804 |
| authorships[4].institutions[0].ror | https://ror.org/027vj4x92 |
| authorships[4].institutions[0].type | company |
| authorships[4].institutions[0].lineage | https://openalex.org/I3018075036, https://openalex.org/I4210111804 |
| authorships[4].institutions[0].country_code | US |
| authorships[4].institutions[0].display_name | Sanofi (United States) |
| authorships[4].author_position | middle |
| authorships[4].raw_author_name | Elizabeth Laws |
| authorships[4].is_corresponding | False |
| authorships[4].raw_affiliation_strings | Sanofi, Bridgewater, NJ, USA |
| authorships[5].author.id | https://openalex.org/A5068343283 |
| authorships[5].author.orcid | https://orcid.org/0000-0001-8517-5456 |
| authorships[5].author.display_name | Eric Mortensen |
| authorships[5].countries | US |
| authorships[5].affiliations[0].institution_ids | https://openalex.org/I186523950 |
| authorships[5].affiliations[0].raw_affiliation_string | Regeneron Pharmaceuticals, Tarrytown, NY, USA |
| authorships[5].institutions[0].id | https://openalex.org/I186523950 |
| authorships[5].institutions[0].ror | https://ror.org/02f51rf24 |
| authorships[5].institutions[0].type | company |
| authorships[5].institutions[0].lineage | https://openalex.org/I186523950 |
| authorships[5].institutions[0].country_code | US |
| authorships[5].institutions[0].display_name | Regeneron (United States) |
| authorships[5].author_position | middle |
| authorships[5].raw_author_name | Eric Mortensen |
| authorships[5].is_corresponding | False |
| authorships[5].raw_affiliation_strings | Regeneron Pharmaceuticals, Tarrytown, NY, USA |
| authorships[6].author.id | https://openalex.org/A5086813222 |
| authorships[6].author.orcid | |
| authorships[6].author.display_name | Hisakatsu Nawata |
| authorships[6].countries | JP |
| authorships[6].affiliations[0].institution_ids | https://openalex.org/I4210141885 |
| authorships[6].affiliations[0].raw_affiliation_string | Immunology Medical, Sanofi K.K., Tokyo, Japan |
| authorships[6].institutions[0].id | https://openalex.org/I4210141885 |
| authorships[6].institutions[0].ror | https://ror.org/040h02z76 |
| authorships[6].institutions[0].type | company |
| authorships[6].institutions[0].lineage | https://openalex.org/I3018075036, https://openalex.org/I4210141885 |
| authorships[6].institutions[0].country_code | JP |
| authorships[6].institutions[0].display_name | Sanofi (Japan) |
| authorships[6].author_position | middle |
| authorships[6].raw_author_name | Hisakatsu Nawata |
| authorships[6].is_corresponding | False |
| authorships[6].raw_affiliation_strings | Immunology Medical, Sanofi K.K., Tokyo, Japan |
| authorships[7].author.id | https://openalex.org/A5030483483 |
| authorships[7].author.orcid | https://orcid.org/0000-0002-0607-8787 |
| authorships[7].author.display_name | Kazuhiko Arima |
| authorships[7].countries | JP |
| authorships[7].affiliations[0].institution_ids | https://openalex.org/I4210141885 |
| authorships[7].affiliations[0].raw_affiliation_string | Immunology Medical, Sanofi K.K., Tokyo, Japan |
| authorships[7].institutions[0].id | https://openalex.org/I4210141885 |
| authorships[7].institutions[0].ror | https://ror.org/040h02z76 |
| authorships[7].institutions[0].type | company |
| authorships[7].institutions[0].lineage | https://openalex.org/I3018075036, https://openalex.org/I4210141885 |
| authorships[7].institutions[0].country_code | JP |
| authorships[7].institutions[0].display_name | Sanofi (Japan) |
| authorships[7].author_position | middle |
| authorships[7].raw_author_name | Kazuhiko Arima |
| authorships[7].is_corresponding | False |
| authorships[7].raw_affiliation_strings | Immunology Medical, Sanofi K.K., Tokyo, Japan |
| authorships[8].author.id | https://openalex.org/A5107442637 |
| authorships[8].author.orcid | https://orcid.org/0000-0002-3658-5704 |
| authorships[8].author.display_name | Daisuke Watanabe |
| authorships[8].countries | JP |
| authorships[8].affiliations[0].institution_ids | https://openalex.org/I4210141885 |
| authorships[8].affiliations[0].raw_affiliation_string | Biostatistics & Programming, Sanofi K.K., Tokyo, Japan |
| authorships[8].institutions[0].id | https://openalex.org/I4210141885 |
| authorships[8].institutions[0].ror | https://ror.org/040h02z76 |
| authorships[8].institutions[0].type | company |
| authorships[8].institutions[0].lineage | https://openalex.org/I3018075036, https://openalex.org/I4210141885 |
| authorships[8].institutions[0].country_code | JP |
| authorships[8].institutions[0].display_name | Sanofi (Japan) |
| authorships[8].author_position | middle |
| authorships[8].raw_author_name | Daisuke Watanabe |
| authorships[8].is_corresponding | False |
| authorships[8].raw_affiliation_strings | Biostatistics & Programming, Sanofi K.K., Tokyo, Japan |
| authorships[9].author.id | https://openalex.org/A5105455465 |
| authorships[9].author.orcid | |
| authorships[9].author.display_name | Xin Lu |
| authorships[9].countries | US |
| authorships[9].affiliations[0].institution_ids | https://openalex.org/I4210111804 |
| authorships[9].affiliations[0].raw_affiliation_string | Sanofi, Bridgewater, NJ, USA |
| authorships[9].institutions[0].id | https://openalex.org/I4210111804 |
| authorships[9].institutions[0].ror | https://ror.org/027vj4x92 |
| authorships[9].institutions[0].type | company |
| authorships[9].institutions[0].lineage | https://openalex.org/I3018075036, https://openalex.org/I4210111804 |
| authorships[9].institutions[0].country_code | US |
| authorships[9].institutions[0].display_name | Sanofi (United States) |
| authorships[9].author_position | middle |
| authorships[9].raw_author_name | Xin Lu |
| authorships[9].is_corresponding | False |
| authorships[9].raw_affiliation_strings | Sanofi, Bridgewater, NJ, USA |
| authorships[10].author.id | https://openalex.org/A5023817287 |
| authorships[10].author.orcid | |
| authorships[10].author.display_name | Jennifer Maloney |
| authorships[10].countries | US |
| authorships[10].affiliations[0].institution_ids | https://openalex.org/I186523950 |
| authorships[10].affiliations[0].raw_affiliation_string | Regeneron Pharmaceuticals, Tarrytown, NY, USA |
| authorships[10].institutions[0].id | https://openalex.org/I186523950 |
| authorships[10].institutions[0].ror | https://ror.org/02f51rf24 |
| authorships[10].institutions[0].type | company |
| authorships[10].institutions[0].lineage | https://openalex.org/I186523950 |
| authorships[10].institutions[0].country_code | US |
| authorships[10].institutions[0].display_name | Regeneron (United States) |
| authorships[10].author_position | middle |
| authorships[10].raw_author_name | Jennifer Maloney |
| authorships[10].is_corresponding | False |
| authorships[10].raw_affiliation_strings | Regeneron Pharmaceuticals, Tarrytown, NY, USA |
| authorships[11].author.id | https://openalex.org/A5012135159 |
| authorships[11].author.orcid | |
| authorships[11].author.display_name | Ariane Dubost-Brama |
| authorships[11].countries | FR |
| authorships[11].affiliations[0].institution_ids | https://openalex.org/I3018075036 |
| authorships[11].affiliations[0].raw_affiliation_string | Sanofi R&D, Chilly-Mazarin, France |
| authorships[11].institutions[0].id | https://openalex.org/I3018075036 |
| authorships[11].institutions[0].ror | https://ror.org/02n6c9837 |
| authorships[11].institutions[0].type | company |
| authorships[11].institutions[0].lineage | https://openalex.org/I3018075036 |
| authorships[11].institutions[0].country_code | FR |
| authorships[11].institutions[0].display_name | Sanofi (France) |
| authorships[11].author_position | middle |
| authorships[11].raw_author_name | Ariane Dubost-Brama |
| authorships[11].is_corresponding | False |
| authorships[11].raw_affiliation_strings | Sanofi R&D, Chilly-Mazarin, France |
| authorships[12].author.id | https://openalex.org/A5085812346 |
| authorships[12].author.orcid | https://orcid.org/0000-0002-7371-6486 |
| authorships[12].author.display_name | Ashish Bansal |
| authorships[12].countries | US |
| authorships[12].affiliations[0].institution_ids | https://openalex.org/I186523950 |
| authorships[12].affiliations[0].raw_affiliation_string | Regeneron Pharmaceuticals, Tarrytown, NY, USA |
| authorships[12].institutions[0].id | https://openalex.org/I186523950 |
| authorships[12].institutions[0].ror | https://ror.org/02f51rf24 |
| authorships[12].institutions[0].type | company |
| authorships[12].institutions[0].lineage | https://openalex.org/I186523950 |
| authorships[12].institutions[0].country_code | US |
| authorships[12].institutions[0].display_name | Regeneron (United States) |
| authorships[12].author_position | middle |
| authorships[12].raw_author_name | Ashish Bansal |
| authorships[12].is_corresponding | False |
| authorships[12].raw_affiliation_strings | Regeneron Pharmaceuticals, Tarrytown, NY, USA |
| authorships[13].author.id | https://openalex.org/A5009953653 |
| authorships[13].author.orcid | |
| authorships[13].author.display_name | Kenji Yahata |
| authorships[13].countries | JP |
| authorships[13].affiliations[0].institution_ids | https://openalex.org/I4210141885 |
| authorships[13].affiliations[0].raw_affiliation_string | Research and Development Division, Sanofi K.K., Tokyo, Japan |
| authorships[13].institutions[0].id | https://openalex.org/I4210141885 |
| authorships[13].institutions[0].ror | https://ror.org/040h02z76 |
| authorships[13].institutions[0].type | company |
| authorships[13].institutions[0].lineage | https://openalex.org/I3018075036, https://openalex.org/I4210141885 |
| authorships[13].institutions[0].country_code | JP |
| authorships[13].institutions[0].display_name | Sanofi (Japan) |
| authorships[13].author_position | last |
| authorships[13].raw_author_name | Kenji Yahata |
| authorships[13].is_corresponding | False |
| authorships[13].raw_affiliation_strings | Research and Development Division, Sanofi K.K., Tokyo, Japan |
| has_content.pdf | False |
| has_content.grobid_xml | False |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://doi.org/10.1016/j.alit.2024.04.006 |
| open_access.oa_status | gold |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | Efficacy and safety of dupilumab with concomitant topical corticosteroids in Japanese pediatric patients with moderate-to-severe atopic dermatitis: A randomized, double-blind, placebo-controlled phase 3 study |
| has_fulltext | False |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T10837 |
| primary_topic.field.id | https://openalex.org/fields/27 |
| primary_topic.field.display_name | Medicine |
| primary_topic.score | 1.0 |
| primary_topic.domain.id | https://openalex.org/domains/4 |
| primary_topic.domain.display_name | Health Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/2708 |
| primary_topic.subfield.display_name | Dermatology |
| primary_topic.display_name | Dermatology and Skin Diseases |
| related_works | https://openalex.org/W3167826726, https://openalex.org/W3180031743, https://openalex.org/W2408550297, https://openalex.org/W3177720512, https://openalex.org/W4237621822, https://openalex.org/W4225834195, https://openalex.org/W3043783927, https://openalex.org/W3041364120, https://openalex.org/W4323567762, https://openalex.org/W2806869485 |
| cited_by_count | 7 |
| counts_by_year[0].year | 2025 |
| counts_by_year[0].cited_by_count | 6 |
| counts_by_year[1].year | 2024 |
| counts_by_year[1].cited_by_count | 1 |
| locations_count | 3 |
| best_oa_location.id | doi:10.1016/j.alit.2024.04.006 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S116585092 |
| best_oa_location.source.issn | 1323-8930, 1440-1592 |
| best_oa_location.source.type | journal |
| best_oa_location.source.is_oa | True |
| best_oa_location.source.issn_l | 1323-8930 |
| best_oa_location.source.is_core | True |
| best_oa_location.source.is_in_doaj | True |
| best_oa_location.source.display_name | Allergology International |
| best_oa_location.source.host_organization | https://openalex.org/P4310320990 |
| best_oa_location.source.host_organization_name | Elsevier BV |
| best_oa_location.source.host_organization_lineage | https://openalex.org/P4310320990 |
| best_oa_location.license | cc-by-nc-nd |
| best_oa_location.pdf_url | |
| best_oa_location.version | publishedVersion |
| best_oa_location.raw_type | journal-article |
| best_oa_location.license_id | https://openalex.org/licenses/cc-by-nc-nd |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | True |
| best_oa_location.raw_source_name | Allergology International |
| best_oa_location.landing_page_url | https://doi.org/10.1016/j.alit.2024.04.006 |
| primary_location.id | doi:10.1016/j.alit.2024.04.006 |
| primary_location.is_oa | True |
| primary_location.source.id | https://openalex.org/S116585092 |
| primary_location.source.issn | 1323-8930, 1440-1592 |
| primary_location.source.type | journal |
| primary_location.source.is_oa | True |
| primary_location.source.issn_l | 1323-8930 |
| primary_location.source.is_core | True |
| primary_location.source.is_in_doaj | True |
| primary_location.source.display_name | Allergology International |
| primary_location.source.host_organization | https://openalex.org/P4310320990 |
| primary_location.source.host_organization_name | Elsevier BV |
| primary_location.source.host_organization_lineage | https://openalex.org/P4310320990 |
| primary_location.license | cc-by-nc-nd |
| primary_location.pdf_url | |
| primary_location.version | publishedVersion |
| primary_location.raw_type | journal-article |
| primary_location.license_id | https://openalex.org/licenses/cc-by-nc-nd |
| primary_location.is_accepted | True |
| primary_location.is_published | True |
| primary_location.raw_source_name | Allergology International |
| primary_location.landing_page_url | https://doi.org/10.1016/j.alit.2024.04.006 |
| publication_date | 2024-05-11 |
| publication_year | 2024 |
| referenced_works | https://openalex.org/W3119334612, https://openalex.org/W4294130696, https://openalex.org/W2778331448, https://openalex.org/W4230355606, https://openalex.org/W2940853643, https://openalex.org/W4385827435, https://openalex.org/W2168273675, https://openalex.org/W6851918356, https://openalex.org/W2003620798, https://openalex.org/W2036163227, https://openalex.org/W2918395485, https://openalex.org/W2588720057, https://openalex.org/W4224435395, https://openalex.org/W3213057710, https://openalex.org/W2734676727, https://openalex.org/W4328107806, https://openalex.org/W4295895500, https://openalex.org/W3036639957, https://openalex.org/W2988092601, https://openalex.org/W2117983771, https://openalex.org/W6842432149, https://openalex.org/W4389886423, https://openalex.org/W90561351, https://openalex.org/W2031370519, https://openalex.org/W1776228394, https://openalex.org/W3086746958, https://openalex.org/W3124764718, https://openalex.org/W4200185498, https://openalex.org/W4225303623, https://openalex.org/W3182787275, https://openalex.org/W3137322934, https://openalex.org/W3124513630, https://openalex.org/W4366590531, https://openalex.org/W4292983887 |
| referenced_works_count | 34 |
| abstract_inverted_index.in | 8 |
| abstract_inverted_index.to | 14 |
| abstract_inverted_index.<18 | 15 |
| abstract_inverted_index.and | 4 |
| abstract_inverted_index.was | 5 |
| abstract_inverted_index.aged | 11 |
| abstract_inverted_index.well | 6 |
| abstract_inverted_index.with | 17, 24 |
| abstract_inverted_index.≥6 | 12 |
| abstract_inverted_index.years | 16 |
| abstract_inverted_index.atopic | 19 |
| abstract_inverted_index.months | 13 |
| abstract_inverted_index.showed | 1 |
| abstract_inverted_index.Japanese | 9 |
| abstract_inverted_index.efficacy | 3 |
| abstract_inverted_index.existing | 25 |
| abstract_inverted_index.patients | 10 |
| abstract_inverted_index.Dupilumab | 0 |
| abstract_inverted_index.tolerated | 7 |
| abstract_inverted_index.consistent | 2 |
| abstract_inverted_index.controlled | 23 |
| abstract_inverted_index.dermatitis | 20 |
| abstract_inverted_index.previously | 21 |
| abstract_inverted_index.therapies. | 26 |
| abstract_inverted_index.insufficiently | 22 |
| abstract_inverted_index.moderate-to-severe | 18 |
| cited_by_percentile_year.max | 99 |
| cited_by_percentile_year.min | 90 |
| corresponding_author_ids | https://openalex.org/A5057294669 |
| countries_distinct_count | 3 |
| institutions_distinct_count | 14 |
| corresponding_institution_ids | https://openalex.org/I4210115833 |
| sustainable_development_goals[0].id | https://metadata.un.org/sdg/3 |
| sustainable_development_goals[0].score | 0.699999988079071 |
| sustainable_development_goals[0].display_name | Good health and well-being |
| citation_normalized_percentile.value | 0.95002849 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | True |